ReviewNutrients2025
Unlocking Mangiferin: A Therapeutic Candidate Revolutionizing Liver Disease Therapy.
Review in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Mangiferin (MF), a natural component widely found in fruits, vegetables, and herbs, has garnered increasing attention for its potent antioxidative properties and therapeutic potential. This bioactive xanthone compound plays a crucial role in mitigating oxidative stress, which is a key factor in the pathogenesis of various diseases, including liver diseases. As a powerful natural antioxidant, MF exhibits a wide range of hepatoprotective effects, making it a promising candidate for liver disease therapy. In this review, we systematically examine the source and chemical properties, synthetic pathways, pharmacokinetic characteristics, and bioavailability enhancement strategies of MF. Furthermore, we explore its mechanisms of action in treating liver diseases, with a focus on its antioxidative properties and their role in modulating liver disease progression. Given the growing burden of liver disease and the limitations of current therapies, this review aims to promote the clinical application of MF as a therapeutic candidate, paving the way for innovative therapeutic strategies for liver diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.